TANFAC Industries Limited (TANF), a major player in the Indian fluorochemicals sector, has delivered a massive 1,800% return over the last 5 years, bringing its market capitalization to approximately ₹6,200 Crore. Backed by marquee institutional investors and high-net-worth individual (HNI) shareholders—including Ashish Kacholia, Vanaja Sundar Iyer, Madhulika Agarwal, and the Malabar Fund—the stock has caught significant attention across the Indian financial landscape.
A research report by Choice Securities has issued a ‘BUY’ rating on TANFAC with a DCF-backed Target Price of ₹3,750, implying a potential upside of ~38–44% from recent levels.
1. Massive Expansion Drive to Multiply Capacity by 1.8x
To capitalize on surging structural demand for specialized fluorochemicals, TANFAC has outlined aggressive capital expenditure (capex) plans totaling over ₹5.9 Billion (~₹590 Crore):
- R-32 Plant Project: Funded through a combination of internal reserves and a fresh capital raise of ~₹3.5 Billion from marquee investors, the primary ₹4 Billion project forms the core of TANFAC’s growth push.
- New Hydrofluoric Acid (HF) Plant: ₹1.5 Billion capex dedicated to adding 17,160 MTPA (metric tonnes per annum) capacity to secure feedstock and enhance operational supply agility.
- New Sulfuric Acid Plant (SAP): ₹0.4 Billion allocated toward an 82,500 MTPA capacity extension.
Once fully commissioned, these three facilities will scale TANFAC’s manufacturing capacity to 1.8 times its current baseline.
2. Strong Revenue Visibility and Margin Expansion
Choice Securities highlights that TANFAC isn’t expanding speculatively—it has built solid forward-looking revenue visibility:
- Long-Term Offtake: 65% of the upcoming R-32 plant capacity is already contracted, ensuring high utilization upon commissioning.
- Better Realizations: R-32 refrigerant gas commands roughly 2x higher realizations compared to commodity Hydrofluoric Acid (HF).
- Margin Expansion: Driven by the shift toward high-value downstream products, operating margins are projected to expand by ~500 bps to ~23% by FY28E.
Growth Forecasts (FY26–FY29E CAGR):
├── Revenue CAGR: ~40%
└── Profit After Tax (PAT) CAGR: ~52%
3. Valuation & Key Investment Highlights
| Parameter | Choice Securities Estimate / Basis |
|---|---|
| Target Price (TP) | ₹3,750 (DCF Methodology) |
| Implied PEG Ratio | 0.67x (FY26–FY29E), indicating attractive growth relative to price |
| Relative Valuation | Peers trade at a 50% premium (38x median forward P/E vs. TANFAC’s ~25x FY28E P/E) |
| Rating | BUY |
4. Key Investment Risks to Watch
While growth prospects remain strong, investors should monitor several key risks associated with the chemical industry:
- Feedstock & Import Dependence: Sensitivity to global price volatility and supply disruptions of critical raw materials.
- Cyclicality: Cyclical demand patterns inherent to basic Hydrofluoric Acid (HF).
- Operational Risks: Strict environmental compliance, safety mandates, and segment/customer concentration.
- Regulatory Risk: Potential risks around non-allocation of production quotas for key refrigerant gases.
Key Takeaway: Backed by marquee investors, solid contracted capacity, and a clear path to 1.8x expansion, TANFAC offers strong fundamental positioning within India’s high-growth specialty fluorochemical landscape.